poisar

Stock

Cingulate Inc. CING

$4.65-4.42%

Overview

CING market data

Price History

CING price chart

Valuation & Profitability

Alpha Vantage
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$4.33
Diluted earnings per share over the trailing twelve months.
Beta
-0.81
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
0.0%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$3.16 – $11.89
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
$24.92
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Alpha Vantage OVERVIEW · market cap $57.1M · P/B 2.57.

Company news

10 captured
Cingulate Joins Russell 3000E IndexBenzinga · Jul 2, 2026, 12:35 PM
Cingulate Receives U.S. Patent For ADHD Treatment CTx-1301, Effective Through December 2042Benzinga · Jun 16, 2026, 12:10 PM
Apple To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For TuesdayBenzinga · Jun 9, 2026, 1:45 PM
Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For MondayBenzinga · Jun 8, 2026, 1:55 PM
Cingulate shares are trading higher after the company announced that the FDA has issued a Complete Response Letter for its NDA for CTx-1301 for the treatment of Attention Deficit/Hyperactivity Disorder.Benzinga · Jun 2, 2026, 2:24 PM
Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption TimesBenzinga · Jun 2, 2026, 12:25 PM
Cingulate Receives FDA Complete Response Letter For ADHD Treatment CTx-1301 Requesting Specific Information About Chemistry, Manufacturing, And Controls, Contains No Concerns Regarding Safety Or EfficacyBenzinga · Jun 2, 2026, 12:05 PM
Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News PendingBenzinga · Jun 2, 2026, 11:55 AM
Cingulate shares are trading higher after HC Wainwright & Co. reiterated its Buy rating on the stock and maintained a $20 price target.Benzinga · May 26, 2026, 4:47 PM
HC Wainwright & Co. Reiterates Buy on Cingulate, Maintains $20 Price TargetBenzinga · May 26, 2026, 10:45 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock